PLoS ONE · 2015 · 21 citations · 33 references
ImmunologyPathologyPlasma CellsTumor BiologyMyeloid NeoplasiaHematological MalignancyOncologyCancer Cell BiologyBone MarrowRadiation OncologyMolecular OncologyCancer ResearchImmune SurveillanceCancer GeneticsCell BiologyImmune Cell DevelopmentMalignant Blood DisorderCancer GenomicsMultiple MyelomaFrequent Down RegulationTumor SuppressorMedicineCell Development
Multiple myeloma (MM) is a malignant clonal expansion of plasma cells in the bone marrow and belongs to the mature B-cell neoplams. The pathogenesis of MM is associated with constitutive NF-κB activation. However, genetic alterations causing constitutive NF-κB activation are still incompletely understood. Since A20 (TNFAIP3) is a suppressor of the NF-κB pathway and is frequently inactivated in various lymphoid malignancies, we investigated the genetic and epigenetic properties of A20 in MM. In total, of 46 patient specimens analyzed, 3 single base pair exchanges, 2 synonymous mutations and one missense mutation were detected by direct sequencing. Gene copy number analysis revealed a reduced A20 gene copy number in 8 of 45 (17.7%) patients. Furthermore, immunohistochemical staining confirmed that A20 expression correlates with the reduction of A20 gene copy number. These data suggest that A20 contributes to tumor formation in a significant fraction of myeloma patients.
33
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman, Michael S. Lawrence, Jonathan J. Keats et al. · Nature · 2011 · 1.4K citations · Full text
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno, Wei Keat Lim, Adina Grunn et al. · Nature · 2009 · 1K citations · Full text